propranolol has been researched along with Lupus Erythematosus, Systemic in 13 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some ephedrine-treated NZM391 mice also were preadministered the beta-AR antagonist propranolol to investigate beta-AR involvement." | 1.33 | The dietary supplement ephedrine induces beta-adrenergic mediated exacerbation of systemic lupus erythematosus in NZM391 mice. ( Cao, L; Huber, VC; Hudson, CA; Kasten-Jolly, J; Lawrence, DA; Mondal, TK, 2005) |
| "A patient with Graves' disease who experienced various allergic reactions to both PTU and MMI is reported." | 1.26 | Lupus-like syndrome--a rare complication in thionamide treatment for Graves' disease. ( Kojima, I; Ogata, E; Takuwa, N, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (76.92) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dorgham, K | 1 |
| Amoura, Z | 1 |
| Parizot, C | 1 |
| Arnaud, L | 1 |
| Frances, C | 1 |
| Pionneau, C | 1 |
| Devilliers, H | 1 |
| Pinto, S | 1 |
| Zoorob, R | 1 |
| Miyara, M | 1 |
| Larsen, M | 1 |
| Yssel, H | 1 |
| Gorochov, G | 1 |
| Mathian, A | 1 |
| Cavallasca, JA | 1 |
| Musuruana, JL | 1 |
| Granero, G | 1 |
| Hudson, CA | 1 |
| Mondal, TK | 1 |
| Cao, L | 1 |
| Kasten-Jolly, J | 1 |
| Huber, VC | 1 |
| Lawrence, DA | 1 |
| McDevitt, DG | 1 |
| Glascow, JF | 1 |
| Takuwa, N | 1 |
| Kojima, I | 1 |
| Ogata, E | 1 |
| Faure, M | 1 |
| Hermier, C | 1 |
| Perrot, H | 1 |
| Jensen, HE | 1 |
| Rasmussen, K | 1 |
| Koch-Weser, J | 2 |
| Harrison, T | 1 |
| Sisca, TS | 1 |
| Wood, WH | 1 |
| Todaro, RT | 1 |
| Meensook, C | 1 |
| Lecchi, RJ | 1 |
| Demeter, E | 1 |
| Kerber, RE | 1 |
| Harrison, DC | 1 |
2 reviews available for propranolol and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Drug therapy. Hydralazine.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Blood Pressure; Cardiac Output; Chronic Disease; Dru | 1976 |
Vasodilator drugs in the treatment of hypertension.
Topics: Administration, Oral; Cardiac Output; Diazoxide; Diuretics; Dose-Response Relationship, Drug; Drug S | 1974 |
1 trial available for propranolol and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
[Experience with the combination of beta receptor blockader and hydralazine in the treatment of hypertension].
Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Headache; Human | 1976 |
10 other studies available for propranolol and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Ultraviolet light converts propranolol, a nonselective β-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; CD4-Positive T-Lymphocytes; Female; Flow Cytometry; | 2015 |
Portal vein thrombosis in systemic lupus erythematosus associated with anticardiolipin antibodies.
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antirheumatic Agents; Carcinoma, Squamous Cell; | 2011 |
The dietary supplement ephedrine induces beta-adrenergic mediated exacerbation of systemic lupus erythematosus in NZM391 mice.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anti-Obesity Agents; Autoantibodies; | 2005 |
Lupus-like syndrome induced by procainamide.
Topics: Arrhythmias, Cardiac; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Procainamide; Prop | 1967 |
Lupus-like syndrome--a rare complication in thionamide treatment for Graves' disease.
Topics: Adult; Autoantibodies; Dexamethasone; Female; Graves Disease; Humans; Lupus Erythematosus, Systemic; | 1981 |
[Cutaneous reactions to propranolol (author's transl)].
Topics: Adolescent; Adrenergic beta-Antagonists; Antibodies, Antinuclear; Drug Eruptions; Eczema; Humans; Lu | 1979 |
Case report. Propranolol-induced lupus syndrome?
Topics: Humans; Hydrazines; Hypertension; Lupus Erythematosus, Systemic; Male; Middle Aged; Practolol; Propr | 1976 |
Lung disease caused by drugs.
Topics: Aspirin; Asthma; Contraceptives, Oral; Drug-Related Side Effects and Adverse Reactions; Eosinophilia | 1969 |
Selective arterial infusion of vasoconstrictor medication in the treatment of gastrointestinal bleeding due to systemic Lupus erythematosus.
Topics: Adult; Epinephrine; Female; Gastrointestinal Hemorrhage; Humans; Injections, Intra-Arterial; Lupus E | 1973 |
Paradoxical electrocardiographic effects of amyl nitrite in coronary artery disease.
Topics: Amyl Nitrite; Angiocardiography; Aortic Valve Stenosis; Blood Pressure; Coronary Circulation; Corona | 1972 |